Catalent: Q4 Earnings Insights

Shares of Catalent CTLT rose 2.7% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 28.57% year over year to $0.90, which beat the estimate of $0.79.

Revenue of $947,600,000 higher by 30.58% year over year, which beat the estimate of $895,510,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Catalent hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 31, 2020

Time: 08:15 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.catalent.com%2Finvestor-center-home%2Fdefault.aspx&eventid=2405942&sessionid=1&key=EFA8925B02543C3411FE00B15784CD43&regTag=&sourcepage=register

Recent Stock Performance

52-week high: $91.95

52-week low: $31.04

Price action over last quarter: Up 25.68%

Company Profile

Catalent is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.